Emergent BioSolutions (EBS) Tops Q3 EPS by 31c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.80 -3.13%
Revenue Growth %: -45.6%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -45.6%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.21, $0.31 better than the analyst estimate of $0.90. Revenue for the quarter came in at $311.8 million versus the consensus estimate of $289.27 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
